EQS-News

Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico - Seite 3

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv and Carragelose are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

^[1]  https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-ca ...

^[2]  https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive ...

---

11.04.2024 CET/CEST This Corporate News was distributed by EQS Group AG. www.eqs.com

---

Language:	English
Company:	Marinomed Biotech AG
	Hovengasse 25
	2100 Korneuburg
	Austria
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.marinomed.com
ISIN:	ATMARINOMED6
WKN:	A2N9MM
Listed:	Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID:	1877827